Corporate Presentation

June 2017
Symbol: BSGM
Disclaimer

This presentation contains forward-looking statements including statements that address activities, events or developments
that BioSig expects, believes or anticipates will or may occur in the future, such as predictions of financial performance,
approvals and launches by BioSig of new products, market acceptance of BioSigs products, market and procedure
projections, financing plans, and related documents. Forward-looking statements are based on BioSigs experience and
perception of current conditions, trends, expected future developments and other factors it believes are appropriate under
the circumstances and are subject to numerous risks and uncertainties, many of which are beyond BioSigs control.

These risks and uncertainties include the timing of approvals for BioSig products, rate and degree of market acceptance of
products, BioSigs ability to develop and market new and enhanced products, the timing of and ability to obtain and
maintain regulatory clearances and approvals for its products and the impact of failure to obtain such clearances and
approvals on its ability to promote its products and train doctors and operators in the use of its products, the timing of and
ability to obtain reimbursement if required of procedures utilizing BioSigs products and the potential impact of current
healthcare reform initiatives thereon, competition from existing and new products and procedures or BioSigs ability to
effectively react to other risks and uncertainties described from time to time in BioSigs SEC filings, such as fluctuation of
financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government
regulation, negative publicity, current worldwide economic conditions and share price volatility.

BioSig does not guarantee any forward-looking statements, and actual results may differ materially from those projected.
Unless required by law, BioSig undertakes no obligation to update any forward-looking statement, whether as a result of
new information, future events or otherwise.

Symbol: BSGM 2
Premiums for Electrophysiology (EP) Tech
Rhythmia
Topera Medical
Medical
Endo
sense

$410 million
Cardio Bard

$350 million
Insight

$331 million
million
million

$275
$272
BioSig & Mayo Clinic - 10 Year Collaboration Signed 3/15/17
Symbol: BSGM 3
Upcoming Major Company Milestones
2017 Q1 Q2 Q3 Q4

Submission Clearance
FDA 510(k)
3Q17 4Q17
Uplist to
UPLIST TO NASDAQ
NASDAQ
PEER REVIEWED Engineering Journal 1H 2017
PUBLICATIONS Cardiology Journal 1H 2017

Mayo Advanced Research Initiative

ON-GOING TRIALS
Mount Sinai VT Scar Model UCLA Advanced VT Mapping

INDUSTRY SYMPOSIA EHRA-CARDIOSTIM June 18-21, 2017

NEW PATENT
APPLICATIONS
Visualization Tools Recording EP Procedures
4
Symbol: BSGM
BioSig Investment Highlights

$4B+ EP Market Growing 10% Annually

Aggressive M&A Activity High Growth Sector
Plan to Uplist to NASDAQ; Potential Dual Listing in EU
FDA 510(k) Submission 3Q17 Expected FDA Clearance 4Q17
World-Class Mgmt, Board of Directors, Scientific Advisory Board
Long Term Collaboration with Mayo Clinic

Symbol: BSGM 5
The Problem Unreliable Information
Equipment in EP Lab Making Noise
MRI CT Scan Robotic Surgical System

Ablation Generator Mapping System

EP Lab For Cardiac Ablation Procedures Electrical noise

obscures needed
information

Symbol: BSGM 6
BioSigs PURE EP System vs. Current Technology
PURE EP System in Red Conventional Recorder in Blue

Micro- Low
Components Amplitude
Revealed Signals
Revealed
Noisy
Signal Noisy
Signal

Symbol: BSGM 7
The Solution: BioSigs Technology

Proprietary Hardware and Software

New Information for the Physician
Targeted Commercial Launch 2018
European Commercial Launch 2019

Potential Reduction in Costs for Hospitals

Symbol: BSGM 8
Need for Technological Innovation
The FDA at the Heart Rhythm Society 2017
This slide was presented by the head of the FDA for EP at a presentation
led by Dr. Andrea Natale (BioSigs Scientific Advisory Board Chairman):

Need for Technological Innovations in AF Ablation

The growing burden of AF has far-reaching public health implications.
Catheter ablation is being widely performed for the treatment of symptomatic drug
refractory AF. However, the outcomes of AF ablation are still suboptimal.
Technological innovations are warranted to improve safety, effectiveness and
procedural efficiency.

www.fda.gov

Symbol: BSGM 9
Large & Fast Growing Market
EP Devices Procedure Growth
Current EP Market is >$4B Worldwide
$8.0 1,500,000 1,350,000
$6.0
$6.0
$ in Billions

Procedures
1,000,000 865,000
$4.0
$4.0

$2.0 500,000

$- -
2016 2020 2015 2020
EP Labs: Estimated 4,500 WW; 3,000 in US
In US by 2020: Expected 422,000 Procedures; Over $3B in Revenues
Driver: Ablation Becoming
First Line of Therapy
Symbol: BSGM 10
Current EP Recording Devices

Lab Systems Pro

15%
EP Workmate
35%
~$1 BILLION
CardioLab Installed Base
50%

Todays Technology
Needs Improvement
Symbol: BSGM 11
PURE EP System Testimonial
The improved resolution
may translate to better
ability to pick up specific
signals and relate them
to specific structure and
substrate.
Samuel J. Asirvatham,
M.D. Mayo Clinic
Link to MD&DI Article: Cutting Out the Noise to Target Arrhythmias
"The dynamic range of the
system is larger - likely will
translate into better ability to
see both large and small
(frequency and amplitude)
signals with similar
resolution. This is a major
problem with present systems,
where in order to see smaller
signals, we have to amplify the
signals, and in doing so, we lose
the ability to see larger signals
without saturating these
signals.
Symbol: BSGM
"The display options are
also more intuitive and
flexible. For example,
different filtering can be
applied to the same
signal and displayed as
separate, simultaneous
signals. Presently this is
not possible with the
existing systems to my
knowledge."
12
PURE EP Development Path
Collaborating with Leading Centers

March, June & June 2016 - July 2016 -

June 2011 June 2013 September 2014 December 2014 November 2015 Present Present

Concept Developed PURE EP System PURE EP System Visit to Mayo Pre-Clinical Advanced Pre-Clinical
with Texas Cardiac Proof of Concept Prototype Test at Clinic to plan Pre- Studies at Mayo Research Program Studies at Mt
Arrhythmia (POC) Test at UCLA Clinical Studies Clinic at Mayo Clinic Sinai in NY
Institute UCLA

Other Collaborations

Brigham And Womens UH Case Medical

Hospital in Boston Center in Cleveland

Symbol: BSGM 13
Presentations and Manuscripts from Pre-Clinical Studies
Enhanced Electrophysiology Recording Improves Signal Acquisition and Differentiation
Presentation by the team from Mayo Clinic at the 13th Annual International Dead Sea Symposium (IDSS) in Tel-Aviv and
available online, March 2016

Enhanced Electrophysiology Recording System

Poster presented at 38th Annual International Conference EMBC 2016, August 2016

Novel Electrophysiology Signal Recording System Enables Specific Visualization of the Purkinje Network and Other High-
Frequency Signals
JACC: Clinical Electrophysiology, Volume 2, Issue 7, Page 850, December 2016

Use of Terminal Unipolar Electrogram Current of Injury as a Novel Marker to Estimate Contact: An Acute Canine Study
Poster Presentation at HRS 38th Annual Scientific Sessions May 2017 in Chicago

Initial Experience with the BioSig PURE EP Signal Recording System: An Animal Laboratory Experience
Publication in The Journal of Innovations in Cardiac Rhythm Management, 8 (2017), 2690-2699 April 2017 issue

Symbol: BSGM 14
Unique Collaboration with Mayo

10-Year Agreement
Technology & Clinical Development
PURE EP Version 2.0
PURE EP Version 3.0
Joint Intellectual Property Filings
Licensing Opportunities
Investment

Symbol: BSGM 15
World-Class Scientific Advisory Board
Andrea Natale, MD,
Executive Medical Director, Texas Cardiac Arrhythmia Institute, St. Davids Medical Center
Chairman
Professor of Medicine & Vice Chair of Division of Cardiovascular Diseases, Department of Medicine;
Samuel Asirvatham, MD program director Clinical Cardiac Electrophysiology Training Program, Mayo Clinic in Rochester,
Minnesota
Assistant Professor of Medicine, Division of Cardiovascular Diseases, Mayo Clinic in Jacksonville,
K. L. Venkatachalam, MD Florida
Kalyanam Shivkumar, MD,
Director, UCLA Cardiac Arrhythmia Center; Professor of Medicine & Radiology
PhD
Mauricio Arruda, MD Director, Clinical Electrophysiology & Pacing, University Hospitals Case Medical Center
Director, Cardiac Arrhythmia Service and a Helmsley Trust Professor of Medicine, Mount Sinai
Vivek Reddy, MD Medical Center in New York
Senior Researcher at Texas Cardiac Arrhythmia Institute; Associate Professor, Albert Einstein College
Luigi Di Biase, MD, PhD of Medicine, Adjunct Professor at the UT Austin

Symbol: BSGM 16
Board of Directors
Kenneth L. Londoner,
Founder, Executive Chairman, CEO, Director; Endicott Management Partners, J & W Seligman & Co
MBA

Roy T. Tanaka Director; Former CEO of BioSense Webster, Johnson & Johnson; Volcano Corp, VytronUS, Coherex Medical

Seth H. Z. Fischer Director; Current CEO & Dir: Vivus, Inc; Former WW Chairman: Johnson & Johnson, Cardiovascular
Patrick J. Gallagher,
Director; Managing Director Laidlaw & Co.; Kinex Pharma; Founder BDR Research Group, Kidder Peabody
MBA
Jeffrey F. ODonnell, Sr. Director; CEO, Chair: Trice Medical; Chair: Mela Sciences; Founder: Embrella Cardiovascular
Jerome B. Zeldis, MD,
Director; CEO of Celgene Global Health & Chief Medical Officer of Celgene Corporation; Chairman: Alliqua
PhD
David Weild IV, MBA Director; Founder & CEO: Weild & Co.; Vice Chairman: NASDAQ; Head of Corporate Finance Prudential

Donald E. Foley Director; CEO & Chair: Wilmington Trust; Sr VP, Treas, & Dir: ITT Corp; Asst Treas: Intl Paper Co.

Symbol: BSGM 17
Proven Management Team
Kenneth L. Founder, Executive Chairman, CEO, Director; Endicott Management
Londoner, MBA Partners, LLC, J & W Seligman & Co

Steve Chaussy, CPA CFO; Liberski Inc, Anna & Co, Penske Automotive, Ford Hogg and Cobbe

VP Clinical Research; VP Clinical/Mkt Dev: RESPICARDIA, Inc.; VP/Sr Dir

Jay O. Millerhagen, Clinical: St Jude Medical; Dir New Product Planning, Brady Mktg, Heart
MS, MBA Failure R&D/Mktg, Bus Alliance Mktg with J&J, GE Healthcare: Boston
Scientific

Managing Director, Europe; Founder: Augeous Consulting SP

Natasha Russkina
Geneva, Switzerland; Bus. Dev. Mngr: IG GROUP, Belarus & London

Co-Founder, Director of Administration; President: Miko Consulting Group,

Lora Mikolaitis
Inc.

Symbol: BSGM 18
EP Sector M&A Activity
Company Proof of Prototype Clinical CE FDA Sales Acquirer/ Valuation
Concept Data Mark Investor
$1.1 Billion
HeartWare Medtronic
June 2016
$25 billion
St. Jude Medical Abbott
April 2016
Auris Surgical $80 million
Hansen Medical Robotics April 2016
Kalila Medical Undisclosed
Formed 2010 Abbott
Feb 2016
nContact $149 million
Formed 2005 Atricure
Oct 2015
CardioInsight $272 million
Formed 2006 Medtronic
June 2015
Topera Medical $350 million
Formed 2010 Abbott
Dec 2014
Endosense SA $331 million
Formed 2003 St. Jude
Aug 2013
Bard EP $275 million
Division of CR Bard Boston Scientific
Nov 2013
Rhythmia Medical $410 million
Formed 2004 Boston Scientific
Oct 2012
19
Symbol: BSGM
BioSig Technologies, Inc. (BSGM)
OTCQB: BSGM
WWW.BIOSIGTECH.COM

Key Company Data (6/01/17)

Recent price: $1.36
52-week range: $1.05 - $2.00
Primary shares i/o: 25.22 million
Float: 12.2 million
Market cap: $34.3 million
Avg Volume (30 day): 48,327 shares

Symbol: BSGM 20
BioSig Investment Highlights

$4B+ EP Market Growing 10% Annually

Aggressive M&A Activity High Growth Sector
Plan to Up List to NASDAQ; Potential Dual Listing in EU
FDA 510(k) Submission 3Q17 Expected FDA Clearance 4Q17
World-Class Mgmt, Board of Directors, Scientific Advisory Board
Long Term Collaboration with Mayo Clinic

Symbol: BSGM 21
Contact BioSig

Ken Londoner
Founder, Executive Chairman, CEO
(203) 644-5200
klondoner@biosigtech.com

Lora Mikolaitis
Co-Founder, Director of Administration
(310) 948-7200
lmikolaitis@biosigtech.com

This document is being provided on a confidential basis by BioSig Technologies, Inc. solely for the information of those persons to whom it is transmitted. No person in any jurisdiction may treat this document as
constituting either an offer to sell or solicitation of an offer to buy any securities in the Company. A prospective subscriber must rely solely on the terms of and disclosure of information including important information
regarding risks and conflicts of interest contained in the Company's final offering memorandum and related documents, the only basis on which subscriptions may be made.

Symbol: BSGM 22
Catheter Ablation vs. Drug Therapy

Destroys arrhythmic Suppresses

tissue to cure
2-8 hours depending on
clinician experience,
disease
1-3 procedures typically
Low risk, minimally
invasive
symptoms, does not BioSigs Goal:
cure
Improve EP lab
throughput
Many drugs taken
indefinitely Reduce complexity,
length & costs of
Possible detrimental procedures
side effects
Improve outcomes &
reduce need for
Not tolerated by
many patients
repeated procedures

Symbol: BSGM 23
BioSigs Focus: Complex Arrhythmias
Normal Heart Rhythm At r i a l F i b r i l l a t i o n Rapid/irregular heart rate
Left Atrium Everyone over 40 has a
Right 1 in 4 lifetime risk
Atrium
Expensive due to
SA Node multiple ablation
procedures needed

Affects > 6M in US

Risk of Stroke 4- to 5-fold

(5th leading cause of
death)

Sources: CDC, http://www.preventaf- Symbol: BSGM 24

strokecrisis.org/files/files/The%20AF%20Report%2014%20April%202012.pdf
VT Signals Difficult to Detect
Ve n t r i c u l a r Rapid / irregular
Normal Heart Rhythm heartbeat in the
Ta c h y c a r d i a ( V T )
Left Ventricle ventricles of the heart
Rapidly fatal if not
SA Node reversed
450,000 Sudden
cardiac deaths in
the US annually
Can be treated
Right
with ablation
Ventricle
Improved signals
should enable more
precise treatments
and less procedures
Symbol: BSGM 25
PURE EP System Pure Signals
For Successful EP Studies and Ablation Treatments

An Electrophysiology (EP) Study tests the electrical conduction system of the heart by recording
ECG signals and intracardiac electrograms.

Catheter Ablation is a low-risk procedure to destroy small areas of heart tissue that cause rapid
and irregular heartbeats to help restore the hearts regular rhythm.

it is Critically Dependent on the Recording System to

Faithfully Acquire/Display Multiple, Low Amplitude Signals

Precise Uninterrupted Real-time Evaluations of Electrocardiograms (ECG) & Electrograms

Symbol: BSGM 26